The Swiss biotech company BioLingus has entered an exclusive technology and marketing collaboration for sublingual delivery with STA Pharmaceuticals, a subsidiary of WuXi AppTec employing more than 16’000 people globally. The partnership gives BioLingus access to global markets and allows for accelerated scaling.
BioLingus, with headquarters in Hergiswil (NW) and offices in Hong Kong and Australia, is specialized in the development of oral (sublingual) delivery of peptides and proteins for chronic diseases and immunotherapy. The startup developed a technology that enables transforming injectable medicines into pills that go under the tongue. Biolingus’ technology is internationally patent protected and has received numerous awards.
The startup has now entered a partnership with STA Pharmaceutical Co., (WuXi STA), a subsidiary of WuXi AppTec, a global pharmaceutical and medical device open-access capability and technology platform company with global operations and over 16’000 employees worldwide. The WuXi platform enables more than 3,000 innovative collaborators from over 30 countries to deliver innovative healthcare products to patients.
Under the terms of the collaboration, WuXi STA will have exclusive access to BioLingus technology for sublingual and buccal delivery in the contract development and manufacturing organization (CDMO) sector. The collaboration will help to integrate the advantages of WuXi STA drug product services further and expedite the development of BioLingus' pipeline and usage of sublingual delivery technology.
BioLingus now joins the number of companies benefiting from WuXi STA. "We entered into this exclusive collaboration with WuXi STA for this technology in the CDMO sector for several reasons. Principally, WuXi STA is one of the world leaders in this field, with an integrated CMC platform from pre-clinical development to commercialization. Furthermore, this partnership will help us develop our own client base on a global scale faster and more broadly than we could do on our own," said Yves Decadt, CEO of BioLingus.
Minzhang Chen, CEO of WuXi STA, added: "We are very pleased to partner with BioLingus and to offer their award-winning sublingual delivery technology to global new drug developers via WuXi STA's integrated CMC platform. This collaboration will, therefore, offer more economical, convenient and effective delivery solutions for patients globally."
(Press release/RAN)
Please login or sign up to comment.
Commenting guidelines